Stroke Patients: Edoxaban's Role in Recurrence Prevention Unveiled

Exploring the Findings from the NOAH-AFNET 6 Trial and Its Implications for Stroke Patients

Jun 18, 2024

∙ Paid

An illustration showing a split scene. On one side, a patient in a hospital bed with medical equipment, symbolizing stroke recovery. On the other side, a close-up of blood cells with a focus on one cell breaking apart, representing bleeding risk. The background should show a heartbeat monitor to symbolize the connection to heart health and atrial fibrillation.

Topline

A recent subanalysis of the NOAH-AFNET 6 trial reveals that edoxaban, an oral anticoagulant, does not significantly reduce the risk of recurrent stroke in patients with a history of stroke or transient ischemic attack (TIA) while increasing the risk of significant bleeding. This finding prompts a re-evaluation of current treatment practices for s…

Continue reading this post for free, courtesy of Naveen Sankar S.

Or purchase a paid subscription.

Just Healthcare

Stroke Patients: Edoxaban's Role in Recurrence Prevention Unveiled

Exploring the Findings from the NOAH-AFNET 6 Trial and Its Implications for Stroke Patients

Topline

Continue reading this post for free, courtesy of Naveen Sankar S.